SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2017

SEGMENT INFORMATION

SEGMENT INFORMATION

17. SEGMENT INFORMATION

The Company operates in one reportable segment—the development and commercialization of novel therapeutic products. The Company has identified its Chief Executive Officer as the Chief Operating Decision Maker, or CODM, who manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating financial performance, the CODM reviews individual customer and product information, while other financial information is reviewed on a consolidated basis. Therefore, results of operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Disclosures about revenues by product and by geographic area are presented below.

Geographic Information

Outside the United States, or ROW, the Company sells avanafil (STENDRA/SPEDRA) through a commercialization licensee principally in the EU. The geographic classification of product sales was based on the location of the customer. The geographic classification of supply, license and milestone revenue was based on the domicile of the entity from which the revenue was earned.

Net product revenue by geographic region was as follows (in thousands):

	Three Months Ended March 31,
	2017							2016
	U.S.		ROW			Total		U.S.		ROW			Total
Qsymia—Net product revenue	$	17,620	$	—		$	17,620	$	12,412	$	—		$	12,412
Qsymia—License revenue		5,000		—			5,000		—		—			—
STENDRA/SPEDRA—Supply revenue		3,775		37			3,812		—		1,526			1,526
STENDRA/SPEDRA —Royalty revenue		—		580			580		826		560			1,386
Total revenue	$	26,395	$	617	(1)	$	27,012	$	13,238	$	2,086	(2)	$	15,324

(1) $0.6 million of which was attributable to Germany.

(2) $2.1 million of which was attributable to Germany.